New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection.
The treatment of hepatitis C virus infection has been advancing at breakneck speeds over the past few years. This article provides an update on the newest drugs available and those currently in development, including newer-generation protease inhibitors, RNA-dependent RNA polymerase, and nonstructural component inhibitors. Also discussed in this article are the regimens developed and the genotypes they target. Treatment of cirrhotic patients and patients who have failed prior therapy is also addressed, as are special populations, such as patients with harder-to-treat genotypes, patients with HIV coinfection, patients who have undergone liver transplantation, and patients with chronic kidney disease. Future developments and economic considerations are also mentioned.
Dr Kardashian is a fellow in the Division of Gastroenterology and Hepatology at Scripps Clinic in La Jolla, California. Dr Pockros is the director of the Liver Disease Center at Scripps Clinic and is the director of clinical research at Scripps Translational Science Institute in La Jolla, California.
A Kardashian
AK
Ara
Dr Kardashian is a fellow in the Division of Gastroenterology and Hepatology at Scripps Clinic in La Jolla, California. Dr Pockros is the director of the Liver Disease Center at Scripps Clinic and is the director of clinical research at Scripps Translational Science Institute in La Jolla, California.
J Pockros
JP
Paul
Hepatitis C virus; direct-acting antiviral agents; nucleoside inhibitors; protease inhibitors; special populations